lercanidipine has been researched along with Metabolic Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dolidze, NM; Gezeli, TD; Tabidze, GA; Tsibadze, TA | 1 |
1 review(s) available for lercanidipine and Metabolic Diseases
| Article | Year |
|---|---|
[Clinical efficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension and metabolic disorders (review)].
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Metabolic Diseases; Risk Factors; Treatment Outcome | 2015 |